 For the treatment of moderate and severe chronic circulatory disorders of peripheral arteries (e.g., arteriosclerosis obliterans, thromboangiitis obliterans, diabetic microangiopathy and Raynaud's phenomenon).Ancrod has been shown to be useful for maintaining anticoagulation in the presence of Heparin-induced thrombocytopenia (HIT) and thrombosis.A small study compared to ancrod to heparin in preventing thrombosis when given to people undergoing arterial graft surgery to treat peripheral arterial disease and found little difference between the two agents.